Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
06
2020
accepted:
28
01
2021
entrez:
25
2
2021
pubmed:
26
2
2021
medline:
6
8
2021
Statut:
epublish
Résumé
Since 2010, nationwide networks of reference centers for sarcomas (RREPS/NETSARC/RESOS) collected and prospectively reviewed all cases of sarcomas and connective tumors of intermediate malignancy (TIM) in France. The nationwide incidence of sarcoma or TIM (2013-2016) was measured using the 2013 WHO classification and confirmed by a second independent review by expert pathologists. Simple clinical characteristics, yearly variations and correlation of incidence with published clinical trials are presented and analyzed. Over 150 different histological subtypes are reported from the 25172 patients with sarcomas (n = 18712, 74,3%) or TIM (n = 6460, 25.7%), with n = 5838, n = 6153, n = 6654, and n = 6527 yearly cases from 2013 to 2016. Over these 4 years, the yearly incidence of sarcomas and TIM was therefore 70.7 and 24.4 respectively, with a combined incidence of 95.1/106/year, higher than previously reported. GIST, liposarcoma, leiomyosarcomas, undifferentiated sarcomas represented 13%, 13%, 11% and 11% of tumors. Only GIST, as a single entity had a yearly incidence above 10/106/year. There were respectively 30, 64 and 66 different histological subtypes of sarcomas or TIM with an incidence ranging from 10 to 1/106, 1-0.1/106, or < 0.1/106/year respectively. The 2 latter incidence groups represented 21% of the patients with 130 histotypes. Published phase III and phase II clinical trials (p<10-6) are significantly higher with sarcomas subtypes with an incidence above 1/106 per. This nationwide registry of sarcoma patients, with exhaustive histology review by sarcoma experts, shows that the incidence of sarcoma and TIM is higher than reported, and that tumors with a very low incidence (1<106/year) are less likely to be included in clinical trials.
Sections du résumé
BACKGROUND
Since 2010, nationwide networks of reference centers for sarcomas (RREPS/NETSARC/RESOS) collected and prospectively reviewed all cases of sarcomas and connective tumors of intermediate malignancy (TIM) in France.
METHODS
The nationwide incidence of sarcoma or TIM (2013-2016) was measured using the 2013 WHO classification and confirmed by a second independent review by expert pathologists. Simple clinical characteristics, yearly variations and correlation of incidence with published clinical trials are presented and analyzed.
RESULTS
Over 150 different histological subtypes are reported from the 25172 patients with sarcomas (n = 18712, 74,3%) or TIM (n = 6460, 25.7%), with n = 5838, n = 6153, n = 6654, and n = 6527 yearly cases from 2013 to 2016. Over these 4 years, the yearly incidence of sarcomas and TIM was therefore 70.7 and 24.4 respectively, with a combined incidence of 95.1/106/year, higher than previously reported. GIST, liposarcoma, leiomyosarcomas, undifferentiated sarcomas represented 13%, 13%, 11% and 11% of tumors. Only GIST, as a single entity had a yearly incidence above 10/106/year. There were respectively 30, 64 and 66 different histological subtypes of sarcomas or TIM with an incidence ranging from 10 to 1/106, 1-0.1/106, or < 0.1/106/year respectively. The 2 latter incidence groups represented 21% of the patients with 130 histotypes. Published phase III and phase II clinical trials (p<10-6) are significantly higher with sarcomas subtypes with an incidence above 1/106 per.
CONCLUSIONS
This nationwide registry of sarcoma patients, with exhaustive histology review by sarcoma experts, shows that the incidence of sarcoma and TIM is higher than reported, and that tumors with a very low incidence (1<106/year) are less likely to be included in clinical trials.
Identifiants
pubmed: 33630918
doi: 10.1371/journal.pone.0246958
pii: PONE-D-20-18848
pmc: PMC7906477
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0246958Déclaration de conflit d'intérêts
No competing interests.
Références
PLoS One. 2018 Apr 5;13(4):e0193330
pubmed: 29621244
BMC Health Serv Res. 2012 Mar 28;12:82
pubmed: 22455759
Eur J Cancer. 2011 Nov;47(17):2493-511
pubmed: 22033323
Cancer Epidemiol. 2019 Dec;63:101590
pubmed: 31520939
Acta Orthop. 2017 Jun;88(3):341-347
pubmed: 28266233
Cancer Epidemiol. 2019 Dec;63:101596
pubmed: 31520938
Clin Cancer Res. 2019 Sep 1;25(17):5295-5300
pubmed: 31217199
Cancer. 2020 Jan 1;126(1):98-104
pubmed: 31536651
J Natl Compr Canc Netw. 2016 Jun;14(6):758-86
pubmed: 27283169
Ann Oncol. 2017 Nov 1;28(11):2852-2859
pubmed: 29117335
N Engl J Med. 2005 Aug 18;353(7):701-11
pubmed: 16107623
BMC Public Health. 2010 Apr 12;10:188
pubmed: 20384990
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95
pubmed: 30285218
Oncologist. 2019 Jun;24(6):e338-e346
pubmed: 30409793
PLoS One. 2011;6(8):e20294
pubmed: 21826194
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv68-iv78
pubmed: 29846513
Ann Oncol. 2020 Nov;31(11):1506-1517
pubmed: 32891793
Ann Oncol. 2019 Jul 1;30(7):1143-1153
pubmed: 31081028
BMC Public Health. 2018 Feb 12;18(1):235
pubmed: 29433465
Semin Oncol. 1997 Oct;24(5):504-14
pubmed: 9344316
BMC Cancer. 2010 Apr 19;10:150
pubmed: 20403160
Clin Sarcoma Res. 2016 Nov 15;6:20
pubmed: 27891213
Oncotarget. 2019 Mar 29;10(25):2462-2474
pubmed: 31069009
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67
pubmed: 29846498
Ann Oncol. 2012 Sep;23(9):2442-2449
pubmed: 22331640
Lancet Oncol. 2017 Aug;18(8):1022-1039
pubmed: 28687376
Acta Orthop Suppl. 2009 Apr;80(334):1-104
pubmed: 19919379
Eur J Cancer. 2013 Feb;49(3):684-95
pubmed: 23079473